Drug Trial Radar · NCT06844357
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 27, 2025
Primary completion
Apr 1, 2029
Study completion Apr 1, 2029
Sponsor
- Lead sponsor
- Zhejiang Raygene Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.
Conditions
- HCC
Interventions
tirapazamineDrug
Intra-arterial injection into the tumor feeding artery
Transarterial Embolization (TAE)Procedure
Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
TACEProcedure
TACE with epirubicin
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: 36 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Zhongda Hospital, Affiliated to Southeast University
Nanjing, Jiangsu, China · Recruiting
Lishui Central Hospital
Lishui, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.